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Abstract
Introduction: Growth arrest-specific gene 6 protein (GAS6) and protein S (ProS) are vitamin K-dependent proteins
present in plasma with important regulatory functions in systems of response and repair to damage. They interact
with receptor tyrosine kinases of the Tyro3, Axl and MerTK receptor tyrosine kinase (TAM) family, involved in
apoptotic cell clearance (efferocytosis) and regulation of the innate immunity. TAM-deficient mice show
spontaneous lupus-like symptoms. Here we tested the genetic profile and plasma levels of components of the
system in patients with systemic lupus erythematosus (SLE), and compare them with a control healthy population.
Methods: Fifty SLE patients and 50 healthy controls with matched age, gender and from the same geographic
area were compared. Genetic analysis was performed in GAS6 and the TAM receptor genes on SNPs previously
identified. The concentrations of GAS6, total and free ProS, and the soluble forms of the three TAM receptors (sAxl,
sMerTK and sTyro3) were measured in plasma from these samples.
Results: Plasma concentrations of GAS6 were higher and, total and free ProS were lower in the SLE patients
compared to controls, even when patients on oral anticoagulant treatment were discarded. Those parameters
correlated with SLE disease activity index (SLEDAI) score, GAS6 being higher in the most severe cases, while free
and total ProS were lower. All 3 soluble receptors increased its concentration in plasma of lupus patients.
Conclusions: The present study highlights that the GAS6/ProS-TAM system correlates in several ways with disease
activity in SLE. We show here that this correlation is affected by common polymorphisms in the genes of the
system. These findings underscore the importance of mechanism of regulatory control of innate immunity in the
pathology of SLE.
Introduction
Systemic lupus erythematosus (SLE) is a chronic auto-
immune disease characterized by an impairment of the
regulation of the immune system [1]. This is reflected in
hyperactivity of lymphocytes, the production of patho-
genic auto-antibodies, and the formation of immune
complexes, which can lead to multi-organ damage.
Although the exact aetiology is not known, one of the
possible triggers of this autoimmune reaction is a deficit
in the process of efferocytosis, the clearance of apoptotic
cells [2]. Under normal circumstances, apoptotic cells
are engulfed by macrophages and other phagocyting
cells using specific mechanisms, different from those of
phagocyting bacteria and other corpuscles [3]. This pro-
vides a clearance of possible auto-antigens in the early
phase of cell death without inducing inflammation or
the immune response. In SLE, however, the clearance of
apoptotic cells by macrophages is impaired, which may
allow apoptotic cells to serve as immunogens for the
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induction of autoreactive T and B cells and drive the
production of auto-antibodies [4].
The reasons for the defective clearance of apoptotic
cells in SLE are not clear. The past decade has provided
significant evidence that the complement cascade,
immunoglobulin (Ig) M or pentraxins as serum amyloid
P-component and C-reactive protein, contribute to the
clearance of apoptotic bodies. Macrophages recognize
apoptotic cells through an array of surface receptors [3].
Among them, the Tyro3, Axl and MerTK (TAM) tyro-
sine kinases play an especially important role in the
clearance of apoptotic cells by macrophages and dendri-
tic cells [5]. Mice lacking the three TAM receptors
rapidly develop lupus-like symptoms, being the MerTK
receptor the most potent mediator in this instance [6-8].
The main ligands that bind to and activate the TAM
family of receptors are growth arrest-specific 6 (GAS6)
and protein S (ProS), which are also capable of binding
to negatively charged residues exposed early in apoptosis
on the membrane surface of the apoptotic cell [9].
GAS6 and ProS are 75 kDa multimodular vitamin K-
dependent glycoproteins (VKDPs) found in chordates,
sharing a 40 to 43% amino acid identity in different spe-
cies. Their modular architecture is identical, containing
an N-terminal g-carboxyglutamic acid (Gla) domain,
interacting with phosphatidylserine containing mem-
branes, followed by four epidermal growth factor-like
domains and two laminin globular-like domains that
contain the interaction site with TAM receptor tyrosine
kinases, the first one having a crucial role [10,11]. GAS6
is expressed in many tissues, including capillary
endothelial cells, vascular smooth muscle cells, and bone
marrow cells. Unlike other VKDPs, GAS6 production in
the liver is minor, and its concentration in plasma is
approximately 1,000-fold lower than that of ProS [12].
ProS has a critical function in regulating coagulation in
several critical steps [13]. ProS circulates as approxi-
mately 40% free ProS and 60% as a complex with C4b-
binding protein (C4BP); only free ProS is active as a
cofactor for activated protein C and a ligand for the
TAM receptor kinases [14]. Lower free ProS concentra-
tion in plasma is associated with an increased risk of
deep venous thromboembolism [15].
TAM receptors undergo a proteolytic processing in
the cell membrane, leading to plasma circulating levels
of extracellular fragments of the receptors (soluble
receptors). These forms have been shown to interact
with the ligands, modifying their function [16,17]. These
soluble fragments could have regulatory functions for
the GAS6/ProS-TAM system, as well as being markers
of its state of activation.
Recently, several studies have focused on the compo-
nents of this system in groups of patients with lupus
[18-20]. Low values of ProS might have important roles
in the pathogenesis of SLE, and acquired ProS deficiency
has been associated with the thrombotic complications
often encountered in these patients [21]. In contrast,
plasma GAS6 concentration was reported to be elevated
in patients with severe sepsis, and septic shock, or
inflammatory diseases without infectious agents and
severe acute pancreatitis. GAS6 concentration in SLE
has been evaluated by two studies, demonstrating either
an increased concentration or similar levels in patients
with lupus [18,22]. A genetic association of single
nucleotide polymorphic variants in the genes of the
GAS6/ProS-TAM system has been determined in cardi-
ovascular disease [23-25]. In the present study we corre-
late the plasma concentration of components of the
system with single nucleotide polymorphisms (SNPs)
characterized in the GAS6/TAM genes.
Materials and methods
Individuals enrolled in the study
Plasma samples from a group of patients with SLE (n =
50) were obtained from the Department of Autoimmune
Diseases Hospital Clínic, University of Barcelona, Barce-
lona, Spain. A group of healthy individuals (n = 50)
without autoimmune disease, bleeding disorders, throm-
bosis or a history of pregnancy loss was obtained from
the Department of Haemostasia and Haemotherapy. The
two groups were matched for ethnicity (all Caucasians),
age (mean age 40 years) and gender (two men and
forty-eight women). Patients with SLE fulfilled the
revised criteria of the American College of Rheumatol-
ogy for the classification of SLE [26]. The main SLE
clinical manifestations evaluated in this study were
defined according to the American Rheumatism Asso-
ciation glossary committee [27]. Disease activity was
scored using the Systemic Lupus Erythematosus Disease
Activity Index (SLEDAI) [28], while the SLE-associated
injury was measured by the Systemic Lupus Interna-
tional Collaborating Clinics/ACR (SLICC/ACR) Damage
Index [29]. The present study was approved by the
Human Experimental Committee of the Hospital Clínic
(Barcelona) and was performed according to the princi-
ples of the Declaration of Helsinki. Informed consent
was obtained from all participants.
Parameter determination in plasma samples
Free and total ProS were determined using standard
clinical laboratory methods (Asserachrom Protein S and
Asserachrom Free Protein S, Stago, Asnières, France).
Values are expressed as percentage of control plasma.
The concentration of the vitamin K-dependent ligand
GAS6, and the extracellular fractions of the receptors,
sTyro3, sAxl and sMerTK were analyzed in plasma from
controls and patients by ELISA. For determination of
GAS6, the technique described by Alciato et al. was
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used, with some modifications [30]. Capture and detec-
tion polyclonal antibodies were obtained from R&D Sys-
tems. The plates were blocked for 1 hour at room
temperature with diluent buffer (PBS with 1% bovine
serum albumin, pH = 7.4). The plates were washed
three times with wash buffer (PBS with 0.05%
Tween20). For the determination of sTyro3 and sMerTK
in plasma, ELISA was performed using previously
matched capture and detection antibodies (Duo Set
reagents from R&D Systems, Minneapolis, MN, USA).
Small modifications were introduced in the protocols of
the manufacturer. For sMerTK determination the dilu-
ent reagent contained 3% fish gelatin instead of albumin,
as indicated by Wu et al. [20]. For the determination of
sAxl, a polyclonal antibody from R&D systems was used
as capture antibody, while a biotinylated antibody was
used as detection reagent. Dilutions of plasma samples
were adapted for each assay. Standard curves were made
by serial dilution of purified proteins in each case. Nega-
tive controls were buffer alone and a plasma pool was
used as the internal standard of the assays.
Genotype determination and analysis
Genomic DNA was extracted from venous blood sam-
ples. Genotype determinations were performed as pre-
viously described, using quantitative real-time PCR [23].
In GAS6 [EMBL: ENSG00000183087], we selected
rs8191973, rs7331124, rs7323932 and rs8191974 SNPs,
which form the haplotype block previously associated
with stroke. In TAM genes, after a search in the public
databases dbSNP, Ensembl and HapMap, we selected ele-
ven SNPs: four in TYRO3 [EMBL: ENSG00000092445],
three in AXL [EMBL: ENSG00000167601] and four in
MERTK [EMBL: ENSG00000153208]. Inclusion criteria
were: to include both validated SNPs with minor allele
frequency (MAF) > 0.05, which were also potentially
functional SNPs (missense, located in putative splice-site
sequences or in both 5’-UP and 3’-DS regions) and/or
were SNPs that tagged common haplotypes (minor hap-
lotype frequency of 0.05), according to Haploview analy-
sis of HapMap information on these genes. Genotyping
was performed by quantitative real-time PCR. SNPs
rs8191973, rs7331124, rs7323932, and rs8191974 in GAS6
and rs869016 in MERTK, were genotyped using FRET
probes in a LightCycler® 480 System (Roche Applied
Science, Penzberg, Germany). Amplification primers and
probes were designed and synthesized by TIBMOLBIOL
(Berlin, Germany). Genotypes of rs2277537, rs16971872,
rs2289743, rs12259 in TYRO3, rs4802113, rs2304234,
rs2304232 in AXL and rs10496440, rs7573344, rs17835605
in MERTK were genotyped by TaqMan probes in an ABI
7900HT instrument (Applied Biosystems, Paisley, UK), fol-
lowing manufacturer’s recommendations. SNP association
analysis was performed as reported previously using the
SPSS package and SNPStats web tool. Detailed protocols
and information on the SNP selection criteria are provided
in Hurtado et al. [23].
Statistical analysis
Statistical Analysis was performed with Graphpad Prism
v 4.02 (Graphpad Software Inc, La Jolla, CA, USA).
Continuous results are expressed as mean ± SD, unless
indicated otherwise. Comparisons were made with Stu-
dent’s t-test for equal variances or the Mann-Whitney
test if variances were different. As treatment with oral
anticoagulation affects ProS and Gas6 [12,31], we per-
formed comparisons between SLE patients and controls
in the whole groups and after excluding patients who
were under oral anticoagulation treatment. Comparisons
among plasma parameters and SLEDAI were performed
using the Kruskal-Wallis test. Correlation among plasma
parameters was evaluated with Pearson’s linear regres-
sion. P-values lower than 0.05 were considered statisti-
cally significant. The numbers of each genotype observed
were compared with those expected for a population in
Hardy-Weinberg equilibrium with the chi-squared test.
Results
Patients
Fifty patients with SLE were analyzed. The main demo-
graphic and clinical characteristics are depicted in Table 1.
Of note, five out of twenty-eight patients (18%) with lupus
nephritis developed renal failure, defined as glomerular fil-
tration rate < 60 mL/minute per 1.73 m2. In addition, five
patients (10%) were on oral anticoagulant therapy.
Plasma values of GAS6/ProS-TAM system parameters in
SLE and controls
The different protein components of the GAS6/ProS-TAM
system were measured in the samples of 50 SLE patients
and 50 age- and sex-matched controls (Table 2). The three
soluble forms of the TAM receptors were increased in the
50 patients of SLE compared with age- and sex-matched
controls (Figure 1a-c). Soluble Tyro3 had the largest
increase in concentration, more than double the concentra-
tion of the control group (1.65 ± 0.93 ng/mL in controls
versus 3.62 ± 1.13 ng/mL in SLE patients), followed by
sAxl (1.3-fold increase), and sMerTK (1.2-fold increase).
In contrast to the receptors, the ligands followed oppo-
site behaviours (Figure 1d-f); while GAS6 values increased
1.2-fold compared to controls, total and free ProS
decreased in SLE patients. The decrease was particularly
important in free ProS, at more than 30% of the control
values. Comparisons were also made after excluding the
five patients on anticoagulant therapy, as ProS and GAS6
concentrations are affected by it [12,31], and there were
similar significant differences (GAS6 32.2 ± 10.3 ng/mL,
P = 0.008; total ProS 87.4 ± 16.0% of control plasma; free
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ProS 71.7 ± 21.0% of control plasma, P < 0.0001in both
cases). After applying the Bonferroni correction for multi-
ple comparisons in the plasma measurements, sTyro3 and
free ProS concentrations remained significantly higher in
the SLE group compared to controls.
Disease activity, severity and plasma values of GAS6/
ProS-TAM system parameters
Several measures of the GAS6/ProS-TAM system corre-
lated with the severity of the disease (Figure 2). For instance,
when we compared the group of patients with a SLEDAI
score lower than 3 (n = 18) with those patients with a
higher SLEDAI score (n = 32), there was a significant differ-
ence in GAS6 plasma concentration (P = 0.005), with 27.0 ±
1.9 ng/mL in the low-score group and 35.3 ± 1.9 ng/mL in
the high score group (Figure 2A). Indeed, the low SLEDAI-
score group had the same GAS6 plasma concentration as
the control group. This difference remained significant
when the five patients on oral anticoagulants were excluded
(P = 0.003). In contrast, the TAM receptors had only mod-
erate increases in the high SLEDAI group for sTyro3 (3.2 ±
1.0 ng/mL vs 3.9 ± 1.1 ng/mL; P = 0.03) (Figure 2B); or
no differences for sAxl (31.3 ± 12.0 ng/mL vs 36.8 ±
15.3 ng/mL; P = 0.26) and sMerTK (19.2 ± 10.3 ng/mL vs
22.3 ± 11.0 ng/mL; P = 0.29) (data not shown). ProS para-
meters were also similar in high and low SLEDAI groups
when the five patients who were receiving oral anticoagula-
tion were excluded from the analysis (total ProS 84.6 ± 3.4%
vs 91.6 ± 3.0%; P = 0.13; free ProS 71.2 ± 4.5% vs 72.4 ±
4.2%; P = 0.8).
GAS6, sMerTK, and sTyro3 showed a significant positive
linear correlation with SLEDAI, but not sAxl (Table 3).
While total ProS showed a negative significant correlation
with SLEDAI, free ProS values showed no significant corre-
lation. In contrast, no parameter correlated with the SLE-
associated injury score, as measured by SLICC, with
sMerTK being marginally significant (Table 3).
Differences in GAS6/ProS-TAM in specific SLEDAI
manifestations
Patients with renal failure (n = 5) presented higher values
of GAS6 (42.5 ± 4.0 ng/mL vs 31.2 ± 1.5 ng/mL;
P = 0.023); MerTK (31.4 ± 7.3 ng/mL vs 20.1 ± 1.4 ng/mL;
Table 1 Demographic and clinical characteristics of patients with systemic lupus erythematosus (SLE) and healthy
controls
SLE patients
(n = 50)
Healthy controls
(n = 50)
Demographic characteristics
Age at study, years,
mean ± SD
40.2 ± 10.5 40.3 ± 10.6
Sex, female:male 48:2 48:2
Clinical characteristics
Arthritis, n (%) 49 (98%)
Skin involvement, n (%) 41 (82%)
Glomerulonephritis (class), n (%) 28 (56%)
Class IV: 21
Class V: 3
Class III: 2
Class II: 2
Haematologic involvement, n (%) 21 (42%)
Hemolytic anemia 22%
Thrombocytopenia 34%
Serositis, n (%) 14 (28%)
Neurological involvement, n (%) 8 (16%)
SLEDAI score, mean ± SD (range) 5.92 ± 5.89 (0, 26)
SLICC score mean ± SD (range) 1.52 ± 1.59 (0, 7)
Oral anticoagulation, n 5 0
SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; SLICC, Systemic Lupus International Collaborating Clinics; n, number of patients or controls.
Table 2 Plasma values of the GAS6/ProS-TAM system in
patients with systemic lupus erythematosus (SLE) and
healthy controls
SLE patients
(n = 50)
Healthy controls
(n = 50)
P
sAxl, ng/mL 34.8 ± 14.3 25.9 ± 15.3 0.0036
sMerTK, ng/mL 21.2 ± 10.8 17.4 ± 12.1 0.0122
sTyro3, ng/mL 3.62 ± 1.13 1.65 ± 0.93 < 0.0001*
GAS6, ng/mL 32.3 ± 1.50 27.2 ± 1.08 0.0067
ProS, total, % 82.6 ± 3.03 102.4 ± 1.52 < 0.0001
ProS, free, % 67.6 ± 3.34 101.0 ± 2.07 < 0.0001*
Quantitative variables as expressed as mean ± standard deviation. *Significant
after Bonferroni correction for multiple comparisons.
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P = 0.024); and Tyro3 (4.6 ± 0.4 ng/mL vs 3.5 ± 0.2 ng/mL;
P = 0.031). When the 28 patients with different degrees of
glomerulonephritis were excluded from the analysis, all
measurements remained significantly different in SLE
patients compared to controls, with the exception of
sMerTK (not shown). From the rest of the manifestations,
only thrombocytopenia showed significant differences in
GAS6 values, increasing to 38.1 ± 3.5 ng/mL compared to
30.0 ± 1.5 ng/mL (P = 0.017), while signs of haemolytic
anaemia increased MerTK values to 27.3 ± 3.7 ng/mL
compared to 19.5 ± 1.6 ng/mL in patients without anaemia
(P = 0.032).
GAS6-TAM genetic variants and plasma concentrations in
lupus and control patients
Next, we genotyped SNPs of the GAS6/ProS-TAM genes
selected from a previously described population of patients
with atherosclerotic disease and controls in the same geo-
graphical area [23,24]. From those determined, three SNPs
showed clear differences among genotypes in their gene
product plasma concentrations. For SNP rs869016 in
MERTK intron 1 (c.61 ± 2737G > A), most of the differ-
ence in sMerTK concentration could be attributed to the
AA group. The concentration of sMerTK increased from
12.3 ± 1.8 ng/mL in five AA controls to 29.3 ± 5.5 ng/mL
in the eight AA homozygote patients. This concentration
was significantly higher compared to the AG and GG
patients (P = 0.019). Genotypes carrying the A allele of
GAS6 intron 8 SNP variant (rs8191974) increased from
26.2 ± 1.3 ng/mL in 33 AA ± AG controls compared to
33.1 ± 1.8 ng/mL in 31 SLE patients (P = 0.002), while
there was no difference in the GG group (Figure 3). In the
case of AXL, the observed increase in sAxl could be attribu-
ted to carriers of the G allele (24.6 ± 5.2 ng/mL in 17 GG ±
AG controls compared to 41.2 ± 3.8 ng/mL in 19 AG SLE
patients), while no differences were observed in the AA
genotype between SLE and controls. No differences in
plasma concentrations were observed in relation to the
other SNPs genotyped.
Discussion
The GAS6/ProS-TAM system of vitamin K-dependent
ligands and tyrosine kinase membrane receptors could
have a prominent role in SLE, based in the observed phe-
notype of TAM knockout mice models [6,8]. Recent
reports have evaluated the plasma concentrations of the
soluble forms of the TAM receptors and ligands in SLE
[18,20,22]. In the present study we measured all parameters
A  B C 
D E F 
Figure 1 Plasma concentrations of the components of the growth arrest-specific gene 6 protein (GAS6)/Protein S (ProS)-Tyro3, Axl
and MerTK receptor tyrosine kinase (TAM) system in systemic lupus erythematosus (SLE) and in normal controls. Normal controls were
matched for age, ethnicity and geographical area (n = 50). Values were significantly different (P < 0.05).
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in a population of SLE patients and compared them with a
control population and with the activity of disease. The
general pattern of variation of the GAS6/ProS-TAM sys-
tem parameters in SLE is similar in the studies available,
although we found a higher increase in sTyro3 and sAxl,
while there was only a moderate increase in sMerTK
plasma concentration, in contrast to a previous work [20].
The concentrations of the three receptors were in the
ranges reported in most previously published studies, with
sTyro3 < sMerTK < sAxl. Remarkably, both ligands, the
vitamin K-dependent ProS and GAS6, were significantly
different in the control and SLE populations, with higher
GAS6 concentration and lower ProS in SLE patients.
Previous results found a negative correlation between dis-
ease and free ProS, but no significant decrease [18]. GAS6
was found to be increased and correlated with SLEDAI in
two studies [22,32], but not in a smaller sample [18]. Most
likely, the differences among studies are due to the intrinsic
heterogeneity of the populations in each case. Some studies
have indicated that specific traits of SLE evaluated in SLE-
DAI, such as nephritis [20,22] or neurologic disorder [18],
affect the values of GAS6 or sMerTK. We confirmed
higher values of both GAS6 and sMerTK in patients with
renal failure. In accordance with these findings, higher
values of GAS6 have been reported in chronic renal failure
[33]. The sMerTK values seem linked to kidney disease, as
the increase was mainly in patients with renal failure. This
was not the case for the other parameters.
A second source of heterogeneity is the effect of specific
genetic factors on the plasma concentrations of GAS6,
sAxl and sMerTK. Different populations are likely to pre-
sent differences in the genetic distribution of the alleles
studied, and this could be reflected in the plasma concen-
trations of the proteins. Indeed certain GAS6 variants
have shown considerable differences between populations
from Europe and Asia [23,24,34,35]. If some of these var-
iants would have functional consequences, this could be
reflected in plasma concentrations of the gene products.
Due to the design and sample size of the study, it was not
our goal to analyze the SNP distribution in SLE compared
to the healthy population. A previous study in a Korean
SLE population found no association between the risk of
SLE and several MERTK polymorphisms, but found an
association with leuco- and/or lymphopenia in SLE
patients [36]. A recent study of GAS6 SNPs showed link-
age with traits of SLE, including vasculitis (rs1803628) and
thrombocytopenia (rs8191974), suggesting that larger stu-
dies could find associations between these genes and the
development of certain disease traits [37].
Several parameters of the GAS6/ProS-TAM system cor-
related with the activity of disease measured through the
SLEDAI score in our study, in line with previous findings
[18,20,22]. We found significant positive correlations of
SLEDAI with GAS6, sMerTK and sTyro3, similar to Wu
et al. [20], but contrary to Ekman et al. [22], the concen-
tration of sAxl did not correlate with the SLEDAI, while
levels were found to be increased in both studies. It is pos-
sible that sAxl is correlated only indirectly with the disease
activity, and thus this correlation is lost in some popula-
tions. It is interesting to note that sMerTK was the only
A  B
Figure 2 Correlation of growth arrest-specific gene 6 protein (GAS6) and sTyro3 with Systemic Lupus Erythematosus Disease Activity
Index (SLEDAI). Systemic lupus erythematosus (SLE) patients were classified according to SLEDAI into a low (n = 18), intermediate (n = 22) or
high activity group (n = 10). Values were significantly different using analysis of variance (ANOVA) (GAS6, P = 0.015; sTyro3, P = 0.021).
Table 3 Linear correlations of plasma values with SLEDAI
and SLICC scores
SLEDAI SLICC
Pearson’s r P Pearson’s r P
GAS6 0.327 0.021 0.187 0.193
Total ProS -0.359 0.01 0.050 0.741
Free ProS -0.233 0.103 0.052 0.735
sAxl -0.008 0.957 0.185 0.198
sMerTK 0.425 0.002 0.285 0.045
sTyro3 0.437 0.001 0.118 0.414
SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; SLICC, Systemic
Lupus International Collaborating Clinics/American College of Rheumatology;
GAS6, growth arrest-specific gene 6 protein.
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parameter of the system correlated with damage caused by
the disease as measured by SLICC.
Although the mechanism and significance underlying the
observed differences in SLE patients cannot be inferred
from the studies published until now, it is interesting to
note that while GAS6 follows the soluble TAM receptors,
augmenting SLE, ProS does not. GAS6 forms a stable com-
plex with sAxl in human serum, where sAxl molar concen-
tration is in excess of GAS6, blocking the activity of the
ligand [38]. Furthermore, it has been shown that the pre-
sence of GAS6 activates the recycling of Axl receptors in
the cell membrane [39]. Therefore, the increase observed
in sTyro3, sAxl and GAS6 could reflect an increase in
TAM regulatory activity due to the inflammation derived
from the illness [40]. In this context, it is interesting to
note that inflammatory molecules such as bacterial lipopo-
lysaccharide induce TAM shedding [41]. The role of GAS6
activation of Axl and MerTK has been shown to be down-
regulatory of the inflammatory innate response for several
of its cellular components, including dendritic cells, natural
killer cells and macrophages [40].
A second mechanism that could be reflecting the asso-
ciation of GAS6/ProS-TAM measurements and SLE is
efferocytosis. Apoptotic cells, if not cleared properly, could
release cellular contents that become self-antigens and
develop the autoimmune reactions characteristic of pathol-
ogies such as SLE [4]. Presence of apoptotic cells in lym-
phatic tissue and decreased engulfment of apoptotic cells
by macrophages and dendritic cells have been reported in
SLE patients [42,43]. TAM kinases, and in particular
MerTK, is essential in the proper clearance of apoptotic
cells [40,44]. Some studies have suggested that the relevant
MerTK ligand is ProS [45,46], but GAS6 has also been
shown to activate MerTK [47]. ProS concentration is
almost 1,000 times that of GAS6 in serum, and ProS has
been shown to be the main serum adjuvant in efferocytosis
[48]. The decrease of ProS detected in SLE patients is not
large enough to be diagnosed as acquired ProS deficiency,
and therefore, it is unlikely to have a strong effect on the
risk of thrombosis. Still, it could have important conse-
quences in the case of apoptotic cell clearance, which
could be accentuated in SLE macrophages and dendritic
cells [42,43,49].
Conclusions
Here we show the association of several parameters
related to the activity of TAM receptors and their
ligands in patients with SLE. As suggested by other
reports, GAS6 and other components of the system
could be good markers of the development of SLE.
Further studies with larger populations are needed in
order to validate this assumption, as well as to deter-
mine the possible genetic components that could be
best linked to the disease.
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(B) MERTK rs869016 (intron 1a, c.61 ± 2737G > A) and (C), AXL rs2304232 (intron 6 c.2169 ± 9A > G). SLE, systemic lupus erythematosus.
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